A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US

Current Medical Research and Opinion

Volumn 25, Issue 6, 2009, Pages 1343-1353

  St Charles, Meaghan ^a   Minshall, Michael E ^a   Pandya, Bhavik J ^b   Baran, Robert W ^b   Tunis, Sandra L ^c  

^a IQVIA   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c IMS Consulting Services   (United States)

Author keywords

Economic modeling; Metformin; Pioglitazone; Rosiglitazone; Type 2 diabetes mellitus

Indexed keywords

ACTOPLUSMET; GLUCOSE; HEMOGLOBIN A1C; LIPID; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; UNCLASSIFIED DRUG;

ADULT; AMPUTATION; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC PATIENT; DRUG EFFICACY; DRUG TOLERABILITY; EYE DISEASE; FEMALE; HEALTH CARE COST; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; QUALITY ADJUSTED LIFE YEAR; ULCER; UNITED STATES;

AGED; COMORBIDITY; COST-BENEFIT ANALYSIS; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DRUG COMBINATIONS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE, HEALTH, REIMBURSEMENT; MALE; METFORMIN; MIDDLE AGED; THIAZOLIDINEDIONES; UNITED STATES;

EID: 67649450096     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990902870084     Document Type: Article

References (48)

1. Kahn S. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 2003;46:3-19 (Pubitemid 36237741)
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006;29:S43-8
3. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States. Atlanta, GA, USA, 2007
4. Roper N, Bilous R, Kelly W, et al. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ 2001;322:1389-1393 (Pubitemid 32523292)
5. UK Prospective Diabetes Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-856
6. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853 (Pubitemid 28416718)
7. UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes (UKPDS 40). BMJ 1998;317:720-726 (Pubitemid 28414302)
8. Clarke P, Gray A, Briggs A, et al. Cost-utility analysis of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 2005;48:868-877 (Pubitemid 40767979)
9. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
10. Jacobs M, Kleisli T, Pio J, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract 2005;70:263-269 (Pubitemid 41539788)
11. Chiquette E, Ramirez G, Defronzo R. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 2004;164:2097-2104 (Pubitemid 39419498)
12. Derosa G, Cicero A, Gaddi A, et al. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallelgroup trial. Clin Ther 2004;26:744-754 (Pubitemid 38736964)
13. Czoski-Murray C, Warren E, Chilcott J, et al. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation. Health Technol Assess 2004;13:1-91 (Pubitemid 38489227)
14. Tilden DP, Mariz S, O'Bryan-Tear G, et al. A lifetime modeled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. Pharmacoeconomics 2007;25:39-54 (Pubitemid 46072367)
15. Chirakup S, Chaiyakunapruk N, Chaikledkeaw U, et al. Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand. Value Health 2008;11(Suppl 1):S43-51
16. Tunis SL, Minshall ME, St. Charles M, et al. Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US. Curr Med Res Opin 2008;24:3085-3096
17. Nissen SE, Wolski K. Effect of pioglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-2471 (Pubitemid 46919772)
18. Moon KT. Rosiglitazone is associated with increased cardiovascular mortality (Editor's note). Am Family Physician 2008;77: available on line http://www.aafp.org/afp/. Last accessed December 2 2008).
19. American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care 2008;31:S12-54
20. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-1540 (Pubitemid 38857422)
21. Riddle MC. Is initial combination therapy effective in the treatment of type 2 diabetes? Nature Clin Prac Endocrinology Metab 2006;2:254-255
22. Derosa G, D'Angelo A, Ragonesi PD, et al. Metforminpioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetes patients with metabolic syndrome. J Clin Pharm Ther 2006;31:375-383 (Pubitemid 44060202)
23. Bell D, Wyne K. Treatment of type 2 diabetes: use of fixed-dose oral combinations. Postgrad Med 2006;119:8-14
24. Grundy S. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2005;47:1093-1100
25. Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision making. Curr Med Res Opin 2004;20:S5-26 (Pubitemid 39349905)
26. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin 2004;20:S27-40 (Pubitemid 39349906)
27. NHANES 1999-2000 Dataset: Diabetes Survey. National Center for Health Statistics, Centers for Disease Control and Prevention. NHANES, 2002
28. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2-9 (Pubitemid 28507114)
29. Phillips SJ, Whisnant JP, O'Fallon WM, et al. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester, Minnesota. Mayo Clin Proc 1990;65:344-359 (Pubitemid 20124303)
30. Miller CD, Phillips LS, Tate MK, et al. Meeting American Diabetes Association guidelines in endocrinologist practice. Diabetes Care 2000;23:444-448 (Pubitemid 30185784)
31. Harris MI. Health care and health status and outcomes for patients with type 2 diabetes. Diabetes Care 2000;23:754-758 (Pubitemid 30414188)
32. Harris MI, Cowie CC, Stern MP. Diabetes in America, 2nd edn. (NIH publication no. 95-1468). Bethesda, Maryland: National Institute of Diabetes and Digestive and Kidney Diseases, 1995
33. Brändle M, Zhou H, Smith BR, et al. The direct medical cost of type 2 diabetes. Diabetes Care 2003;26:2300-2304 (Pubitemid 36993316)
34. Moss SE, Klein R, Klein BE. The prevalence and incidence of lower extremity amputation in a diabetic population. Arch Intern Med 1992;152:610-616
35. Gold MR, Siegel JE, Russell LB, et al. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996
36. O'Brien JA, Patrick AR, Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 2003;25:1017-1038
37. DRG Guidebook. A Comprehensive Resource to the DRG Classification System. St. Anthony Publishing, 2001
38. Predicted costs and outcomes from reduced vibration detection in people with diabetes in the U.S. Diabetes Care 2003;26:2305-2310 (Pubitemid 36993317)
39. Bullano MF, Al-Zakwani IS, Fisher MD, et al. Differences in hypoglycemia event rates and associated cost-consequence in patients initiated on long-acting and intermediate-acting insulin products. Curr Med Res Opin 2005;21:291-298 (Pubitemid 40469905)
40. Drug Topics Red Book. Montvale, NJ, Medical Economics Company, 2004
41. Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660-667 (Pubitemid 29517951)
42. O'Brien J, Shompe L, Kavanagh P, et al. Direct medical costs of complications resulting from type 2 diabetes in the U.S. Diabetes Care 1998;21:1122-1128 (Pubitemid 28368519)
43. Kantor J, Margolis DJ. Treatment options for diabetic neuropathic foot ulcers: A cost-effectiveness analysis. Dermatol Surg 2001;27:347-351 (Pubitemid 32290859)
44. US Department of Labor, Bureau of Labor Statistics, Consumer Price Index for the Healthcare Sector, 2006. Washington DC: Division of Consumer Prices and Price Indexes, 2006
45. American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care 2004;27:2262-2265
46. Tarn T, Smith M. Pharmacoeconomics guidelines around the world. ISPOR Connections 2004;10:5-15
47. Halpern EF, Weinstein MC, Hunink MG, et al. Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. Med Dec Making 2000;20:314-322 (Pubitemid 30470727)
48. American Diabetes AssociationEconomic costs of diabetes in the U.S. in 2007. Diabetes Care 2008;31:1-20